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https://doi.org/10.1016/j.jacl.2018.03.0BACKGROUND: Familial chylomicronemia syndrome (FCS) is an ultra-rare phenotype that is usu-
ally caused by biallelic mutations in the LPL gene encoding lipoprotein lipase, or less often in APOC2,
APOA5, LMF1, or GPIHBP1 genes encoding cofactors or interacting proteins.
OBJECTIVES: We evaluated baseline phenotypes among FCS participants in a phase 3 randomized
placebo-controlled trial of volanesorsen (NCT02211209).
METHODS: Baseline clinical, fasting, and postfat load metabolic markers were assessed. Targeted
next-generation DNA sequencing plus custom bioinformatics was used to genotype subjects.
RESULTS: Among 52 FCS individuals, 41 had biallelic LPL gene mutations (LPL-FCS patients):
82%, 7%, and 11% were missense, nonsense, and splicing variants, respectively. Eleven individuals
had non-LPL-FCS; 2 had mutations in APOA5, 5 in GPIHBP1, and 1 each in LMF1 and APOC2 genes,
respectively. Two other individuals were double heterozygotes, each with 1 normal LPL allele. All sub-
jects had extremely high triglycerides (TGs) and chylomicrons, but very low levels of other lipoproteins.search Institute, Schulich School of
sity, 4288A - 1151 Richmond Street
da.
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hyperlipoproteinemiaCompared with LPL-FCS individuals, non-LPL-FCS individuals were very similar for most traits, but had
significantly higher postheparin LPL activity, higher 4-hour postprandial insulin and C-peptide levels; and
higher low-density lipoprotein cholesterol levels. In non-LPL-FCS individuals compared to those with
LPL-FCS, there were also nonsignificant trends toward lower levels of total and chylomicron TGs, lower
4-hour postprandial chylomicron TG levels, and higher very-low-density lipoprotein TG levels.
CONCLUSION: Thus, LPL FCS and non-LPL FCS are largely phenotypically similar. However, LPL
FCS patients have lower postheparin LPL activity and a trend toward higher TGs, whereas low-density
lipoprotein cholesterol was higher in non-LPL-FCS patients.
 2018 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Familial chylomicronemia syndrome (FCS) is an
extremely rare genetic condition that affects between 1
and 10 per million individuals.1 The hallmark of FCS
includes severe fasting chylomicronemia, with plasma tri-
glyceride (TG) . 1000 mg/dL (.11.3 mmol/L), often
with grossly visible lipemic serum.1–6 Chylomicrons are
derived from dietary fat and under normal metabolic condi-
tions, are rapidly cleared from the serum postprandially,
generally within 3–4 hours.1–6 Clearance is largely medi-
ated through the hydrolyzing action of lipoprotein lipase
gene (LPL), located on the endothelial surface of adipose
and muscle tissue.7 The phenotype of FCS includes at least
one physical manifestation of chylomicronemia, which
include eruptive xanthoma, lipemia retinalis, pancreatitis,
or hepatosplenomegaly.5,6 Although severe hypertriglyceri-
demia (TG . 10 mmol/L or 880 mg/dL) is relatively com-
mon with a prevalence of w 1 in 600 in North America,
only a small fraction of these individuals have FCS.1,5,6
FCS follows an autosomal recessive pattern of inheritance
and results predominantly (.90%) from biallelic mutations
in the LPL gene encoding lipoprotein lipase (LPL)1,5,6; this
form we abbreviate herein as LPL-FCS. The remainder are
caused by biallelic mutations in 4 additional genes involved
in supporting or enabling LPL function, namely APOC2,
APOA5, LMF1 and GPIHBP1, which encode, respectively,
apolipoprotein (apo) C-II and A-V, lipase maturation factor
1 (LMF1) and glycosylphosphatidylinositol-anchored high-
density lipoprotein (HDL)-binding protein 1 (GPIHBP1),1,5,6
and we abbreviate this group of patients as non-LPL-FCS.
The role of each of these gene products in lipolysis of TG
is discussed elsewhere.1,4–6
Given the extreme rarity of these conditions, especially
of non-LPL-FCS, no prior studies have directly compared
clinical and biochemical features of the different mo-
nogenic causes of FCS. Here, we evaluate phenotypic dif-
ferences between LPL-FCS and non-LPL-FCS patients.
Methods
Participants
The study included data from clinically identified FCS
participants who were screened and included in a phase 3randomized placebo-controlled trial of volanesorsen
(NCT02211209). Briefly, the trial duration was 52 weeks,
and subjects were randomized 1:1 to receive either vol-
anesorsen 300 mg SC or placebo injections. The primary
outcome was percent change in TG levels at 13 weeks.
Inclusion criteria for the clinical trial included a personal his-
tory of pancreatitis and with documented chylomicronemia or
TGvalues exceeding10mmol/L and genetic testing or posthe-
parin lipolytic assay consistent with FCS. Patients without
pancreatitis could be eligible up to a maximum of 28% of all
patients. The study enrolled adult patients (age $18 years)
with a history of chylomicronemia as evidenced by documen-
tation of lactescent serum in the fasting state, or fasting TG
measurement $ 10 mmol/L (880 mg/dL). The diagnosis of
FCS required documentation of at least one of the following:
(1) known biallelic loss-of-function mutations in LPL,
APOC2, APOA5, GPIHBP1, or LMF1 genes; (2) postheparin
plasma LPL activity of #20% of normal; plus (3) fasting
TG $ 8.4 mmol/L (750 mg/dL) at screening. Patients were
willing to follow a restrictive diet (#20 g fat per day). The pa-
tients included for analysis here were derived from screening
our confirmatory testing on referred samples from study sub-
jects in the clinical trial. Subjects gave informed consent for
DNA sequencing, which was performed under Western Uni-
versity Research Ethics protocol 07920E.
Clinical and biochemical assessments
Baseline lipids, lipoproteins, apolipoproteins, and meta-
bolic assays were performed on fasting plasma as
described.8,9 Fasting venous blood samples were taken
10 minutes preintravenous and postintravenous infusion
of heparin (50 U/kg), and total postheparin lipolytic activity
was determined as described.10,11 A subset of markers was
also examined 4 hours after liquid-formulated high-fat test
meal (4800 kJ, 130 g of fat, 17 g of protein and 21 g of
carbohydrate).
Molecular analysis
Genomic DNA was isolated from whole blood as
described.12 Genomic libraries of indexed and pooled pa-
tient samples were generated for target candidate genes in
lipid metabolism. These included the coding regions,
.150 base pairs (bp) at intron-exon boundaries and
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ative genes for monogenic chylomicronemia, including
LPL, APOC2, APOA5, LMF1, and GPIHBP1. The tar-
geted next-generation DNA sequencing and custom bio-
informatic pipeline are known collectively as
‘‘LipidSeq’’.12,13 Prepared DNA libraries from each pa-
tient sample were assayed using the MiSeq personal
sequencer (Illumina, San Diego, CA). The method has
mean .300-fold coverage for each base. Sanger
sequencing was used to confirm all variants.
Annotation and evaluation of observed variants
Format for storing sequence and quality files derived
from the MiSeq output were processed individually using a
custom-automated workflow in CLC Genomics Workbench
version 8.5.1 (CLCbio, Aarhus, Denmark) for sequence
alignment, variant calling, producing a variant call format
file, and target region coverage statistics. Variant annotation
was performed using annotation tool for genetic vari-
ants14,15 using customized scripts (http://annovar.
openbioinformatics.org/en/latest/).
There is no consensus on the procedure to attribute
causality or pathogenicity to FCS variants detected by next-
generation sequencing. Fortunately, many variants detected
in monogenic chylomicronemia genes have had a long
history of archiving and annotation, as well as abundant
publications of functional consequences. For instance, .
150 individual variants previously reported as being
causative in LPL deficiency are reported in the Human
Gene Mutation Database (http://www.biobase-
international.com/product/hgmd).16–18
Annotated coding and noncoding (610 bp from adjacent
exon) variants in variant call formats were first filtered to
select the rare variants according to minor allele
frequencies , 1% in 1000 Genomes Project (1 KG),19
Exome Variant Server20 or Exome Aggregation Con-
sortium21 databases. Polymorphism Phenotype Version
2,22 Sorting Intolerant from Tolerant,23,24 and Combined
Annotation Dependent Depletion25 scores were used to
evaluate the deleteriousness of the filtered coding variants.
Splicing-based Analysis of Variants26 and Automated
Splice Site and Exon Definition Analyses27 were used to
identify rare deleterious splicing variants.
Novel variants found in this study were determined to be
likely causative when (1) they had no listed allele
frequencies in 1 KG, Exome Variant Server or Exome
Aggregation Consortium databases, no consensus genetic
variant identification number in the National Center for
Biotechnology Information database of single nucleotide
polymorphisms, and/or were not reported in Human Gene
Mutation Database or University College London familial
hypercholesterolemia database; (2) for coding variants, a
deleterious score for .2 in silico algorithms; and (3) for
noncoding variants, a deleterious score for .1 in silico
algorithm. Copy number variants, sometimes referred to as
‘‘del-dup’’ mutations, were determined using a custombioinformatics approach. Hereafter, the term ‘‘mutation’’ is
used interchangeably with ‘‘rare definite or very likely
causative variant’’ for the sake of brevity.
As controls for our annotation pipeline, we used sequence
data from the 1 KG database. Standard criteria based on
standards of the American College of Medical Genetics, and
also on published functional studies where available, were
used to assess the potential pathogenicity of identified
mutations. Individuals with biallelic pathogenic mutations
in LPL were classified as ‘‘LPL-FCS’’, whereas those with
pathogenic mutations in the other genes were classified as
‘‘non-LPL-FCS’’. Simple heterozygotes for loss-of-
function mutations were excluded from the analysis.
Statistical analysis
Statistical analyses were conducted using SAS v9.4
(SAS Institute, Cary, NC). Between-group differences for
mean quantitative traits were evaluated with Wilcoxon
signed-rank test for nonparametric sample distribution,
whereas differences in discrete traits were evaluated using
chi-square analysis with Fisher’s exact test. Statistical
significance was defined as P , .05 for all comparisons.
Our study sample afforded 84% power to detect a 50% dif-
ference in a quantitative trait whose standard deviation was
20% of the mean with 2-sided alpha 5 0.05.Results
Classification and mutation distribution
Of 67 individuals with phenotypic data who underwent
targeted next generation sequencing, 41 had likely or
definitely pathogenic biallelic LPL gene mutations; of these
82%, 7%, and 11% were missense, nonsense, and splicing
variants, respectively (see Supplementary Table 1). DNA
quality for 1 patient from Quebec was inadequate for Lip-
idSeq; in this case, we made an exception and accepted re-
sults from the certified provincial DNA testing facility,
which diagnosed homozygosity for the founder LPL
p.P234L loss of function variant. An additional 11 individ-
uals had non-LPL-FCS, of whom 2 (22%) had biallelic mu-
tations in APOA5, 5 (45%) had biallelic mutations in
GPIHBP1, 1 (11%) has biallelic mutations in LMF1, 1
(11%) had biallelic mutations in APOC2, and 2 were dou-
ble heterozygotes for mutations in LPL and either APOA5
(11%) or LMF1 (11%). The remainder of individuals,
with a clinical FCS phenotype, but in whom genetic testing
was not fully confirmatory, were excluded from this anal-
ysis. The mutations detected in study subjects are shown
in Supplementary Tables 1 and 2.
Clinical and biochemical features
Numerous clinical, demographic, and biochemical fea-
tures were determined from studied individuals (Table 1).
Hegele et al Sub-phenotypes of familial chylomicronemia 923Non-LPL-FCS individuals were younger at screening than
LPL-FCS cases (38.3 6 12.3 vs 47.1 6 12.8 years,
P 5 .075). As expected, compared with LPL-FCS individ-
uals, non-LPL-FCS individuals had significantly higher
postheparin LPL activity (39.7 6 29.8 vs 6.3 6 5.8 U,
P 5 .0028). In addition, low-density lipoprotein (LDL)
cholesterol, determined directly by ultracentrifugation,
was significantly higher in individuals with non-LPL-FCS
compared with LPL-FCS (28.9 6 8.1 vs 22.1 6 10.4 mg/
dL [0.57 6 0.27 vs 0.75 6 0.21 mmol/L] P 5 .027),Table 1 Characteristics of molecularly characterized familial chylom
Clinical or biochemical feature LPL
Number of individuals 4
Sex (% female) 6
Age at screening 47.1
Body mass index (kg/m2) 24.0
History of acute pancreatitis (%) 8
Age of onset of pancreatitis (y) 25.6
Postheparin LPL activity at baseline (mmol/L/min) 6.3
Total cholesterol (mg/dL)
(mmol/L)
300.9
7.78
Triglycerides (mg/dL)
(mmol/L)
2613
29.5
LDL cholesterol (mg/dL; by ultracentrifuge)
(mmol/L)
22.1
0.57
HDL cholesterol (mg/dL; by precipitation)
(mmol/L)
15.2
0.39
Non-HDL cholesterol (mg/dL)
(mmol/L)
284.9
7.36
Apo A-I (mg/dL) 92.6
Apo B-100 (mg/dL) 59.5
Apo B-48 (mg/dL) 11.4
Apo C-III (mg/dL) 27.4
Chylomicron triglycerides (mg/dL)
(mmol/L)
2296
25.94
VLDL cholesterol (mg/dL)
(mmol/L)
31.3
0.81
VLDL triglycerides (mg/dL)
(mmol/L)
244.4
2.76
Chylomicron plus VLDL apo C-III content (mg/dL) 26.7
HDL apo C-III content (mg/dL) 1.26
Glucose (mg/dL)
(mmol/L)
93.7
5.21
Triglycerides 4 h postprandial (mg/dL)
(mmol/L)
10,031
113.3
Apo B-48 4 h postprandial (mg/dL) 41.08
Chylomicron triglycerides 4 h postprandial (mg/dL)
(mmol/L)
9229
104.3
Glucose 4 h postprandial (mg/dL)
(mmol/L)
408.7
22.7
Insulin 4 h postprandial (U/L) 97.0
C-peptide 4 h postprandial (U/L) 20.7
apo, apolipoprotein; HDL, high-density lipoprotein; LDL, low-density lipopr
tions in the LPL gene encoding lipoprotein lipase; non-LPL-FCS, familial chylom
APOA5, LMF1, or GPIHBP1, which encode, respectively, apo C-II, apo A-V, lipase
ing protein 1; NS, not significant; VLDL, very-low-density lipoprotein.although levels in both subgroups were very low. Apo B
levels were not significantly different. Finally, compared
with LPL-FCS individuals, non-LPL-FCS individuals had
higher postprandial insulin (302.7 6 159.3 vs
97.0 6 137.1 U/L; P 5 .0089) and higher postprandial C-
peptide levels (32.5 6 12.3 vs 20.7 6 6.2, P 5 .0492).
Compared with LPL-FCS individuals, non-LPL-FCS in-
dividuals had a nonsignificant trend lower total (TGs)
(20.79 6 10.6 vs 29.5 1 14.8 mmol/L [1840 6 938 vs
2613 6 1307 mg/dL] P 5 .091), chylomicron TGicronemia subjects
-FCS non-LPL-FCS P-value (Wilcoxon)
1 11
1.0 72.7 NS
6 12.8 38.3 6 12.3 NS (.075)
6 5.6 24.6 6 6.7 NS
5.4 72.7 NS
6 16.5 27.8 6 8.5 NS
6 5.8 39.7 6 29.8 .0028
6 125.4 242.5 6 86.2 NS
6 3.24 6.27 6 2.23
6 1307 1840 6 938 NS (.091)
6 14.8 20.79 6 10.6
6 10.4 28.9 6 8.1 .027
6 0.27 0.75 6 0.21
6 4.1 15.7 6 3.3 NS
6 0.11 0.41 6 0.09
6 124.5 226.8 6 87.1 NS
6 3.22 5.86 6 2.25
6 13.8 99.2 6 26.0 NS
6 18.0 60.3 6 13.6 NS
6 7.11 10.1 6 7.97 NS
6 12.1 28.4 6 12.7 NS
6 1298 1462 6 894 NS (.060)
6 14.7 16.52 6 10.1
6 26.0 40.4 6 23.2 NS
6 0.67 1.04 6 0.60
6 144.2 325.9 6 145.7 NS (.059)
6 1.63 3.68 6 1.65
6 12.6 25.6 6 14.2 NS
6 0.56 1.11 6 0.39 NS
6 13.8 99.4 6 23.9 NS
6 0.77 5.52 6 1.33
6 5125 7467 6 4844 NS
6 57.9 84.4 6 54.7
6 23.09 36.51 6 31.79 NS
6 4973 6045 6 4525 NS (.082)
6 56.1 68.3 6 51.1
6 92.8 531.6 6 244.1 NS
6 5.16 29.5 6 13.6
6 137.1 302.7 6 159.3 .0089
6 6.2 32.5 6 12.3 .0492
otein; LPL-FCS, familial chylomicronemia syndrome due to biallelic muta-
icronemia syndrome due to biallelic mutations in the either the APOC2,
maturation factor 1, or glycosylphosphatidylinositol-anchored HDL-bind-
924 Journal of Clinical Lipidology, Vol 12, No 4, August 2018(16.52 6 10.1 vs 25.94 6 14.7 mmol/L [1462 6 894 vs
22966 1298 mg/dL] P 5 .060), 4-hour postprandial chylo-
micron TGs (68.3 6 51.1 vs 104.3 6 56.1 mmol/L
[6045 6 4525 vs 9229 6 4973 mg/dL] P 5 .082) and
higher very-low-density lipoprotein (VLDL) TGs
(3.68 6 1.65 vs 2.76 6 1.63 mmol/L [325.9 6 145.7 vs
244.4 6 144.2 mg/dL] P 5 .059).
There were no significant differences in other measured
biochemical variables, including traditional and nontradi-
tional lipid, lipoprotein, and apolipoprotein variables.
Furthermore, most variables from advanced lipoprotein
analysis and from postprandial studies were similar between
groups. There was no significant difference in acute
pancreatitis history between non-LPL-FCS and LPL-FCS
groups (72.7% vs 85.4%, respectively) or age of first episode
of pancreatitis (27.8 6 8.5 vs 25.66 16.5, respectively). We
repeated these analyses post hoc, excluding the LPL p.P234L
homozygote whose diagnosis was determined by traditional
sequencing only; all statistical comparisons and interpreta-
tion of results remained the same (data not shown).
Discussion
Although most patients with monogenic chylomicrone-
mia have biallelic, loss-of-function variants in LPL, a sub-
stantial minority has the phenotype due to mutations in the
4 remaining minor genes. A direct head-to-head comparison
of clinical and biochemical features among individuals with
LPL-related and non-LPL–related monogenic chylomicrone-
mia has not yet been reported, generally because these pa-
tients are so rare, and consistent harmonized methods have
not been used in a larger cohort of individuals. Here, because
of the comprehensive assessments of these individuals due to
their involvement in a clinical trial, we had a unique collec-
tion of phenotypically and genotypically well-characterized
individuals with monogenic chylomicronemia to allow for
a detailed assessment of phenotypic differences according
to the main underlying molecular classes.
Our findings primarily indicate that for most fasting and
dynamic metabolic measures, individuals with monogenic
chylomicronemia are phenotypically similar whether the
underlying cause is biallelic mutations in LPL or one of the
other 4 genes. The difference in postheparin LPL activity
was expected based on our understanding of the biochem-
istry and genetic basis of the different forms of the condition.
Individuals with mutations in non-LPL genes, by definition,
had normal LPL enzyme, and thus, there would be less ex-
pected lipolytic compromise under the conditions of the
ex vivo lipolytic assay. We note in Supplementary Table 3
that ex vivo lipolysis is lower in patients with LMF1 and
GPIHBP1 mutations than in the other non-LPL-FCS genetic
subgroups, but not as low as for LPL-FCS patients. Under
in vitro conditions, the deficiencies resulting from LMF1
and GPIHBP1 mutations that would otherwise impair
in vivo function become less relevant. Similarly, the defi-
ciencies resulting from mutations in APOA5 and APOC2
can be rescued because the in vitro test substrate containssome normal apolipoproteins. Thus, on balance, non-LPL
mutation patients had higher LPL activity. The trend toward
significantly higher levels of chylomicrons and TGs seen in
LPL-mutation positive patients suggests that LPL deficiency
may manifest with somewhat more severe chylomicronemia
than FCS resulting from mutations in non-LPL genes.
Of particular note, total cholesterol valueswere high inboth
groups, whereas LDL,HDL,VLDLcholesterol levelswere all
low in both LPL-FCS and non-LPL-FCS groups. This high-
lights a fundamental feature of the metabolic defect in FCS.
With absent or minimal LPL activity, there is a significant
impairment in conversion ofTG-rich particles to their remnant
lipoproteins, which generates a cascading impairment in pro-
duction of subsequent smaller lipoprotein subfractions, for
which these remnants are the initial substrate. Each step of
the lipoprotein metabolism pathway involves lipolysis of TG
via LPL for conversion to a smaller lipoprotein species (ie,
from chylomicrons to chylomicron remnants to VLDL to
VLDL remnants and intermediate density lipoprotein to
LDL). Although LPL-deficient individuals commonly exhibit
elevated total cholesterol values, the cholesterol measured is
predominantly present within chylomicrons, with a TG to
cholesterol ratio ofw20:1, with VLDL, intermediate density
lipoprotein and LDL cholesterol all typically at very low
levels. HDL cholesterol is similarly low due to a decrease in
available cholesterol from its primary sources: VLDL, LDL,
and peripheral tissues. This does not hold true, however, for in-
dividualswith other secondary or polygenic causes of elevated
TGs, inwhichLPL is generally functional, and all lipoproteins
and their remnants can be present and elevated to varying de-
grees, along with an increase in cardiovascular risk. This key
concept has significant implications when selecting appro-
priate therapy.Although secondary and polygenic (typeV) hy-
pertriglyceridemia patients who have some residual LPL
activity can often be effectivelymanagedwith fibrates or other
oral agents, this is not expected to be effective in patients with
LPL deficiency, who require more targeted TG-specific
therapy.
Further subdividing the non-LPL-FCS subgroup by geno-
type allows for some additional anecdotal observations (see
Supplementary Table 3). For instance, in the LMF1-deficient
patient, plasma apo A-I is very high, consistent with a
concomitant low hepatic lipase activity affecting apo A-I-
containing particles, as would be expected given the role
of LMF1 in maturation of both lipases. Although in this pa-
tient, there is no obvious difference in baseline LDL and
HDL cholesterol levels, it is notable that total and especially
postprandial TGs are very high. Furthermore, the TG levels
in the APOC2- and APOA5-deficient patients appear some-
what lower than in the LPL-FCS group, as might be ex-
pected. In addition, the apo C-III content of various
particles does not appear to differ between genotypes.
Finally, the double heterozygotes who each have 1 normal
functioning LPL allele have, as expected, the lowest TG
levels at baseline and especially postprandially.
The significantly higher level of LDL cholesterol seen in
patients with non-LPL-FCS compared with the LPL-FCS
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a less severe impairment of LPL activity in these patients,
or the presence of concomitant secondary causes, compared
with the LPL-FCS group. It may also suggest a minor or in-
direct role of APOC2, APOA5, LMF1, or GPIHBP1 in LDL
processing or clearance, or potentially the clustering of
other unmeasured risk genes in this subgroup compared
with those with LPL-FCS. Some support for this may
come from studies that have shown an association between
mutations in APOA5 and APOC2 and hypercholesterole-
mia.28 Environmental, or gene-environment interactions,
may also be playing a role. Interestingly apo B levels
were not significantly different between the 2 groups,
although specific B-100 and B-48 assays were not per-
formed. Further investigation is required to fully mechanis-
tically define such potential differences.
The tendency of non-LPL mutation carriers to have
somewhat worse indices of insulin resistance suggests
that this secondary factor may be playing an underlying
role in this subgroup. Alternatively, perhaps the LPL defect
leads to greater requirements for glucose in peripheral tis-
sues with improved insulin sensitivity and lower glucose
levels, assuming the islets are functioning normally. In
addition, some of the non-LPL gene product mechanisms
may be predisposing to somewhat compromised insulin
sensitivity, in addition to their major effects on chylomicron
and lipoprotein metabolism. However, the similarity of the
remainder of the phenotypes suggests that regardless of eti-
ology, large effect mutations directly affecting LPL or one
of its critical interacting factors results in a severe pheno-
type that is clinically and biochemically similar irrespective
of the molecular etiology. It would be important to rigor-
ously evaluate insulin sensitivity in individuals subdivided
according to FCS genotype class.
The pancreatitis rates were high in both groups (75%
and 85%, respectively); however, it is important to note that
this was as a result of the clinical trial selection criteria,
which included a personal history of pancreatitis, and
should not be misinterpreted as prevalence rates for
pancreatitis in either genotype.
Limitations
Even though we have collected a unique and relatively
large group of these extremely rare individuals, the sample
size is small, and it is possible that more subtle differences
in some of these variables would be apparent with a larger
number of subjects, particularly those with non-LPL
monogenic chylomicronemia. Furthermore, we did not
have sufficient numbers of individuals to further subdivide
according to minor gene etiology or mutation type.
Because these individuals were studied in a trial of an in-
hibitor of apo C-III, it would have been informative to
have collected not just apo C-III content in subfractions
but also apo E and apo A-V, however, these were not avail-
able. We note that apo C-III content was available in TG-
rich particles (chylomicrons plus VLDL) and also in HDL;overall, these were not statistically different between the
genotypic classes.
In addition, it is important to note that the trial inclusion
criteria limited this data analysis to relatively severe cases
of chylomicronemia. This has the potential to miss
important differences between LPL-FCS and non-LPL-
FCS that may have been seen if those with milder pheno-
types were included. It is also important to note that
different mutations in both LPL and non-LPL genes could
present with a wide phenotypic spectrum based on the
severity of functional compromise that results from a given
mutation. We also excluded heterozygous LPL mutation-
positive patients from analysis; however, it is possible
that heterozygous null mutation carriers may present with
a phenotype that overlaps with milder homozygous or com-
pound heterozygous mutation-positive individuals and
further analysis based on degree of functional compromise
could be informative. Finally, it might also have been infor-
mative to examine the individuals with a clinical FCS
phenotype but in whom genetic testing or LPL activity
were not fully confirmatory, although such patients would
not be easily classified in this experimental design.
Future directions
This study compared phenotypes of the individuals tested
who presented with a clinical FCS phenotype and had a
confirmed genetic basis for their severe chylomicronemia. It
is possible that the remaining individuals have as-yet
unidentified mutations causing true FCS, or they may simply
have severe secondary or polygenic (type V) chylomicrone-
mia. The features of these 15 individuals were not compared
with those who had confirmatory genetic testing in our study.
For some lipidologists, the diagnosis of FCS should include
genetic testing, although the ability to make a diagnosis
based on predictive clinical features alone is highly attrac-
tive. It is beyond the scope of this study to recommend the
necessity for genetic testing to diagnose patients with true
biallelic FCS from among the multitude of those with severe
hypertriglyceridemia. However, once genetic testing has
been performed, and individuals with FCS are subdivided
between biallelic LPL and non-LPL subgroups, the between-
genotype clinical and biochemical differences are subtle. A
comparison between individuals with a clinical FCS pheno-
type but no genetic diagnosis to those who have identified
mutations could be informative. Some preliminary work sug-
gests that some predictive features may include a personal
history of pancreatitis, low body mass index and low apo
B levels (unpublished data).
In summary, we found that patients with LPL-related
and non-LPL–related monogenic chylomicronemia are
largely phenotypically similar, but that LPL-FCS has lower
postheparin LPL activity and somewhat higher chylomi-
crons and TGs, whereas LDL cholesterol was higher in
non-LPL-FCS. It remains to be determined whether these
2 subgroups of patients differ with respect to other attri-
butes, including the response to interventions.
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Patient mutation
status Type
Mutation name and
zygosity
Number
of patients
Homozygous SNV p.P234L homozygote 8
p.G215E homozygote 3
p.D277N homozygote 2
p.Y329X homozygote 2
p.I221T homozygote 2
p.G166S homozygote 2
p.W113R homozygote 1
p.V206A homozygote 1
p.R270H homozygote 1
p.L330P homozygote 1
p.H210R homozygote 1
nonsense/
frameshift
p.D277D fs X4
homozygote
2
p.A61A fs X28
homozygote
1
intronic
SNV
intron 6 22A.T
homozygote
2
intron 7 17A.G
homozygote
1
Double
heterozygote
(LPL and
GPIHBP1
genes)
SNV/intronic
SNV
p.P234L heterozygote;
GPIHBP1, intron
1 14C.T
heterozygote
1
Homozygous and
CNV in
additional gene
(GPIHBP1)
SNV/CNV p.A185T homozygote 1
Compound
heterozygous
SNV/SNV p.G215E heterozygote
and p.R270C
heterozygote
2
p.W113R heterozygote
and p.H163R
heterozygote
1
p.G81D heterozygote
and p.F212L
heterozygote
1
p.G215E heterozygote
and p.P234L
heterozygote
1
p.G215E heterozygote
and p.V96L
heterozygote
1
p.G215E heterozygote
and p.I221T
heterozygote
1
SNV/intronic
SNV
p.A61V homozygote
and intron 2 21G.C
homozygote**
1
p.G215E heterozygote,
and intron 1 15G.C
heterozygote
1
LPL, lipoprotein lipase; SNV, single nucleotide variant; CNV, copy number v
*Average taken if data available for more than one patient with mutation.
**Individual is a complex homozygote for both a missense SNV and introntus and LPL activity
LPL activity
pretreatment*
(umol/L/min)
LPL activity
post-treatment* CNV state
Previously
reported
(reference
numbers)
7.4 8.7 – 29,30
7.4 8.7 – 31–33
3.6 3 – 34
6.45 3.85 – 35
18.9 11.8 – 36,37
3.1 3.2 – 38
1.8 1.8 – 39
7.4 4.8 – 40
4.9 1.8 – 41,42
5.9 9.6 – 43
2.6 ND – No
ND 11.2 – No
6.1 5.2 – No
2.9 3.6 – 44
6.9 1.8 – No
7.5 8 – 29,30
19.2 ND GPIHBP1, exon
3–4 deletion,
heterozygote
43
3.15 2.6 – 31–33
3.6 3.4 – 39,45
2.3 ND – 46
No
2.1 ND – 29–33
14.8 11.6 – 31–33,47
3.4 3.5 – 31–33,36,37
6.2 1.8 – 31–33
3.5 2.4 – 31–33
ariant; ND, not determined; -, absent.
ic variant, which each may be pathogenic.
Supplementary Table 2 Non-lipoprotein lipase gene (non-LPL) mutation status and LPL activity
Gene Mutation CNV state
LPL activity
pretreatment*
(umol/L/min)
LPL activity
post-treatment*
Previously
reported?
APOA5 p.Q330Q fs X6
homozygote
– 37 4 No
p.L253P homozygote – 56.4 – 7,48
APOC2 intron 3 1 1G.C
homozygote
APOC2, exon
1 deletion
(noncoding),
homozygote
80 – No
LMF1 p.P248S homozygote – 31.7 13.5 No
GPIHBP1 p.A6D homozygote – 16.1 14.6 No
p.Q132X homozygote – – 4.6 No
Double
heterozygote
LPL 1 other
LPL p.G215E
heterozygote;
APOA5 p.A315V
heterozygote
– 80 – 31–33
No
LPL p.R116Q
heterozygote; LMF1
p.R233X
heterozygote
– – – 44
No
CNV – GPIHBP1, deletion, homozygote 1.8 – No
– GPIHBP1, exon
3–4 deletion, homozygote
14.9 17.3 7
– GPIHBP1, exon
3–4 deletion, homozygote
– 3.9 49
LPL, lipoprotein lipase; SNV, single nucleotide variant; CNV, copy number variant; ND, not determined; –, absent.
*Average taken if data available for more than one patient with the genotype.
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Supplementary Table 3 Characteristics of molecularly characterized familial chylomicronemia subjects
Clinical or
biochemical feature LPL APOC2 APOA5 LMF1 GPIHBP1
Double
heterozygote
P-value
(overall)
Number of individuals 41 1 2 1 5 2 –
Sex (% female) 61.0 100.0 100.0 100.0 60.0 50.0 NS
Age at screening 47.1 6 12.8 56 46.5 6 6.4 39 33.8 6 11.9 32.0 6 17.0 NS
Body mass index
(kg/m2)
24.0 6 5.6 20.5 23.6 6 1.98 17.9 22.4 6 4.21 36.2 6 3.39 .045
History of acute pancreatitis (%) 85.4 100.0 50.0 100.0 60.0 100.0 NS
Age of onset of pancreatitis (y) 25.6 6 16.5 41 26.0 24.0 24.3 6 6.03 29.0 6 14.1 NS
Postheparin LPL activity at baseline (mmol/L/min) 6.3 6 5.8 80.0 46.7 6 13.7 31.7 10.9 6 7.93 80.0 ,.0001
Total cholesterol (mg/dL)
(mmol/L)
300.9 6 125.4 188 246.5 6 143.5 362 254.8 6 53.9 175.5 6 122.3 NS
7.78 6 3.24 4.86 6.37 6 3.71 9.36 6.59 6 1.39 4.53 6 3.16
Triglycerides (mg/dL)
(mmol/L)
2613 6 1307 1254 1969 6 1790 2683 2096 6 627.3 944 6 1001 NS
29.5 6 14.8 14.2 22.2 6 20.2 30.3 23.7 6 7.08 10.7 6 11.3
LDL cholesterol (mg/dL; by ultracentrifuge)
(mmol/L)
22.1 6 10.2 28 30.5 6 10.6 20 27 6 7.81 37 6 8.49 NS
0.57 6 0.26 0.72 0.79 6 0.27 0.52 0.70 6 0.20 0.96 6 0.22
HDL cholesterol (mg/dL; by precipitation)
(mmol/L)
15.2 6 4.1 14 18 18 13.6 6 1.67 18.5 6 6.36 NS
0.39 6 0.11 0.36 0.47 0.47 0.35 6 0.043 0.48 6 0.16
Non-HDL cholesterol (mg/dL)
(mmol/L)
284.9 6 124.6 174 228.5 6 143.5 344 241.2 6 53.4 157 6 128.7 NS
7.36 6 3.22 4.50 5.91 6 3.71 8.90 6.24 6 1.38 4.06 6 3.33
Apo A-I (mg/dL) 92.6 613.8 79 136 6 11.3 140 85.8 6 12.3 85.5 6 0.71 ,.0001
Apo B-100 (mg/dL) 59.5 6 18.0 55 69.15 6 2.62 66.3 52.6 6 13.2 70.6 6 20.3 NS
Apo B-48 (mg/dL) 11.4 6 7.11 4.88 3.62 6 2.73 18.1 14.3 6 8.21 4.5 6 5.62 NS
Apo C-III (mg/dL) 27.4 6 12.1 19.39 31.9 6 11.8 38.6 25.9 6 11.1 30.6 6 27.1 NS
Chylomicron triglycerides (mg/dL)
(mmol/L)
2296 6 1298 959 1551 6 1730 2123 1780 6 624.2 501.5 6 623 NS
25.94 6 14.7 10.8 17.5 6 19.5 24.0 20.1 6 7.05 5.66 6 7.03
VLDL cholesterol (mg/dL)
(mmol/L)
31.3 6 26.0 28 36.5 6 3.54 67 34.2 6 10.4 49.5 6 57.3 NS
0.81 6 0.67 0.72 0.94 6 0.092 0.76 0.88 6 0.27 1.28 6 1.48
VLDL triglycerides (mg/dL)
(mmol/L)
244.4 6 144.2 238 312 6 1.41 449 290 6 95.5 394 6 355 NS
2.76 6 1.63 2.69 3.52 6 0.016 5.07 3.27 6 1.08 4.45 6 4.01
Chylomicron plus VLDL apo C-III content (mg/dL) 26.7 6 12.6 – – – 24.4 6 11.05 28.5 6 26.5 NS
HDL apo C-III content (mg/dL) 1.26 6 0.56 0.92 – – 1.15 6 0.50 1.09 6 0.071 NS
Glucose (mg/dL)
(mmol/L)
93.7 6 13.8 79.0 93.5 6 3.54 167 90.0 6 5.5 105 6 4.24 ,.0001
5.21 6 0.77 4.39 5.19 6 0.20 9.28 5 6 0.31 5.83 6 0.24
Triglycerides 4 h postprandial (mg/dL)
(mmol/L)
10031 6 5125 7706 6124 6 4019 18173 7042 6 3090 1331 NS
113.3 6 57.9 87.0 69.1 6 45.4 205.2 79.5 6 34.9 15.0
Apo B-48 4 h post-prandial (mg/dL) 41.08 6 23.09 42.1 29.4 6 28.1 114.52 29.2 6 13.7 3.87 .021
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Chylomicron triglycerides 4 h postprandial (mg/dL)
(mmol/L)
9229 6 4973 6473.5 4396 6 3650 15685 5784 6 3250 583.5 NS
104.3 6 56.1 73.09 49.6 6 41.2 177.1 65.3 6 36.7 6.59
Glucose 4 h postprandial (mg/dL)
(mmol/L)
408.7 6 92.8 420.5 943 365 6 15.6 564.5 .0003
22.7 6 5.16 23.4 52.4 20.3 6 0.87 31.4
Insulin 4 h postprandial (U/L) 97.0 6 137.1 – 413.2 527.4 177.9 6 16.1 216.8 .022
C-peptide 4 h postprandial (U/L) 20.7 6 6.1 – 38.1 49.1 27.7 6 9.95 20.0 .0015
Apo, apolipoprotein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LPL-FCS, familial chylomicronemia syndrome due to biallelic mutations in the LPL gene encoding lipoprotein lipase; non-
LPL-FCS, familial chylomicronemia syndrome due to biallelic mutations in the either the APOC2, APOA5, LMF1, or GPIHBP1, which encode, respectively, apo C-II, apo A-V, lipase maturation factor 1, or
glycosylphosphatidylinositol-anchored HDL-binding protein 1; NS, not significant; VLDL, very-low-density lipoprotein.
P-values calculated from analysis of variance and indicates an overall difference between classes. Pairwise comparisons between individual classes were not performed.
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